VALUE-Dx is the first Innovative Medicines Initiative project initiated by 6 in vitro diagnostic companies who joined forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. Unique in its multidisciplinary consortium, it involves clinicians, microbiologists, health economists, social scientists, and industry, to help build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.

VALUE-Dx will focus its research on community care, which is defined as the first point of contact with health services. Innovative and cost-effective diagnostics could transform clinical care, especially in community care settings where the majority of antibiotics are prescribed, by reducing uncertainty about potential benefit antibiotics may offer to individuals. Through a thorough understanding of value indicators and barriers to the adoption of diagnostics, VALUE-Dx will develop and improve health economic models and policy recommendations with the objective of reducing AMR in Community-Acquired Acute Respiratory Tract Infections.

Each of the work packages are collaborating to achieve the overall objective of transforming medial practice to achieve more personalised, evidence-based antibiotic prescription and use in the community care settings to combat AMR.